推荐产品
![PERK抑制剂I，GSK2606414 GSK2606414 is a cell-permeable, highly potent inhibitor of EIF2AK3/PERK (IC₅₀ = 0.4 nM; [ATP] = 5 µM). Targets PERK in its inactive DFG conformation at the ATP-binding region.](/deepweb/assets/sigmaaldrich/product/structures/180/559/efa716dc-d5fe-4339-a6f0-0103084fc04a/640/efa716dc-d5fe-4339-a6f0-0103084fc04a.png)
等級
pharmaceutical primary standard
API 家族
stavudine
製造商／商標名
EDQM
應用
pharmaceutical (small molecule)
格式
neat
儲存溫度
2-8°C
SMILES 字串
CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O
InChI
1S/C10H12N2O4/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8/h2-4,7-8,13H,5H2,1H3,(H,11,14,15)/t7-,8+/m0/s1
InChI 密鑰
XNKLLVCARDGLGL-JGVFFNPUSA-N
正在寻找类似产品? 访问 产品对比指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Stavudine for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
相關產品
产品编号
说明
价格
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 2
閃點（°F）
Not applicable
閃點（°C）
Not applicable
N Clumeck
Antiviral therapy, 3 Suppl 4, 39-43 (2000-03-21)
Current guidelines for treatment of human immunodeficiency virus (HIV) disease favour the use of triple-drug combinations consisting of two nucleoside analogue reverse transcriptase inhibitors (NRTIs) plus a protease inhibitor to achieve maximum suppression of HIV replication. There is considerable evidence
Alain Makinson et al.
Expert opinion on drug safety, 7(3), 283-293 (2008-05-09)
Western randomized trials and prospective cohorts in resource-limited settings have proven virological success with stavudine-based highly active antiretroviral therapy. However, stavudine is no longer recommended in first-line treatments in these two settings due to its intrinsic toxicities and side effects.
John C Martin et al.
Antiviral research, 85(1), 34-38 (2009-10-27)
The occasion of this 25th anniversary issue encouraged us to reminisce about the important history of the discovery of the dideoxynucleoside analogues for the treatment of HIV/AIDS and to chronicle our thoughts about a particular exciting and rewarding period of
M Hurst et al.
Drugs, 58(5), 919-949 (1999-12-14)
Stavudine is a thymidine nucleoside analogue which is phosphorylated intracellularly to an active metabolite, stavudine 5'-triphosphate. This metabolite inhibits HIV replication, either by competing with thymidine 5'-triphosphate for incorporation into viral DNA by reverse transcriptase or by causing premature termination
S A Riddler et al.
Antiviral research, 27(3), 189-203 (1995-06-01)
Stavudine, 2',3'-didehydro-3'-deoxythymidine (D4T), is a potent inhibitor of HIV-1 reverse transcriptase in vitro. In clinical studies, stavudine has excellent oral bioavailability in excess of 80%. The dose-limiting toxicity is peripheral neuropathy, which occurred in 15% of stavudine versus 6% of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门